Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acne Vulgaris
Acanya(TM) Gel, a New Treatment for Moderate to Severe Acne, Launched by Coria Laboratories
March 27th, 2009
Coria Laboratories, the newly expanded dermatology division of Valeant Pharmaceuticals International (NYSE:VRX), announced the commercial launch of Acanya(TM) Gel (clindamycin phosphate 1.2% and benzoyl peroxide 2.5%) indicated for the once-daily treatment of acne vulgaris in patients 12 years and older. Evaluated in clinical studies enrolling over 3,200 subjects with moderate to severe acne vulgaris, Acanya Gel is the only fixed combination antibiotic and benzoyl peroxide (BPO) medication FDA-approved for the once-daily treatment of both non-inflammatory and inflammatory lesions of acne. In pivotal Phase III clinical trials, Acanya Gel showed...
Source: Health Business Week (2009-03-27)
|
